絞り込み

16555

広告

Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with (RAPID): a randomised placebo controlled trial.

著者 Major G , Bradshaw L , Boota N , Sprange K , Diggle M , Montgomery A , Jawhari A , Spiller RC ,
Gut.2018 Sep 25 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (6view , 0users)

Full Text Sources

Miscellaneous

Clostridium difficile infection (CDI) recurs after initial treatment in approximately one in four patients. A single-centre pilot study suggested that this could be reduced using 'follow-on' rifaximin treatment. We aimed to assess the efficacy of rifaximin treatment in preventing recurrence.
PMID: 30254135 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード